Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $5.9 million.

  • Revolution Medicines' Gains from Investment Securities rose 36887.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 48515.49%. This contributed to the annual value of $44.6 million for FY2024, which is 7641.17% up from last year.
  • Per Revolution Medicines' latest filing, its Gains from Investment Securities stood at $5.9 million for Q3 2025, which was up 36887.31% from $18.9 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Gains from Investment Securities high stood at $49.1 million for Q4 2024, and its period low was -$3.9 million during Q1 2024.
  • Moreover, its 5-year median value for Gains from Investment Securities was $1.3 million (2024), whereas its average is $7.6 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 684160.16% in 2021, then tumbled by 146538.46% in 2024.
  • Quarter analysis of 5 years shows Revolution Medicines' Gains from Investment Securities stood at $35.5 million in 2021, then tumbled by 89.86% to $3.6 million in 2022, then skyrocketed by 365.48% to $16.8 million in 2023, then skyrocketed by 192.82% to $49.1 million in 2024, then tumbled by 87.89% to $5.9 million in 2025.
  • Its Gains from Investment Securities was $5.9 million in Q3 2025, compared to $18.9 million in Q2 2025 and -$2.4 million in Q1 2025.